CRISPR Therapeutics AG (CRSP) Gains from Investment Securities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Gains from Investment Securities across 12 years of filings, most recently posting $716931.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $716931.0, up 131.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $716931.0 (down 97.25% YoY), and the FY2025 annual result was $6.7 million, down 7.42% from the prior year.
• Gains from Investment Securities came in at $716931.0 for Q1 2026 at CRISPR Therapeutics AG, down from $8.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $15.2 million in Q4 2024 to a low of -$6.1 million in Q1 2022.
• The 5-year median for Gains from Investment Securities is $1.1 million (2022), against an average of $3.3 million.
• Across the five-year window, Gains from Investment Securities tumbled 195.49% in 2022 and jumped 2276.26% in 2023, its largest moves.
• CRISPR Therapeutics AG's Gains from Investment Securities stood at -$219000.0 in 2022, then surged by 2276.26% to $4.8 million in 2023, then soared by 217.98% to $15.2 million in 2024, then tumbled by 45.14% to $8.3 million in 2025, then plunged by 91.38% to $716931.0 in 2026.
• The last three Gains from Investment Securities figures came in at $716931.0 (Q1 2026), $8.3 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.